Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mailliez

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Bulletin Du Cancer|January 7, 2010
[Chemotherapy induced emesis: pathophysiology and prevention]A Mailliez, J Bonneterre
Gynecologie, Obstetrique & Fertilite|January 14, 2014
[What do clinicians do with the results of the systematic staging imaging at the time of the breast cancer diagnosis?]A Turpin, A Mailliez, P Vennin, et al.
British Journal of Cancer|August 26, 2010
Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patientsA Mailliez, C Baldini, J T Van, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 6, 2024
Breast Cancer Prognosis in Young BRCA1/BRCA2 Mutation Carriers: A Retrospective Hospital-based Cohort StudyF Hego, M Barthoulot, S Chretien, et al.
Journal of Neuro-Oncology|March 5, 2013
A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancerE Le Rhun, S Taillibert, F Zairi, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2018
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trialS A Hurvitz, R G W Quek, N C Turner, et al.
ESMO Open|May 4, 2024
Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohortN Epaillard, A Lusque, W Jacot, et al.
ESMO Open|July 25, 2021
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)D Dano, A Lardy-Cleaud, A Monneur, et al.
ESMO Open|September 18, 2025
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohortR Varnier, D Pérol, W Jacot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)H Bonnefoi, T Grellety, O Tredan, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Bulletin Du Cancer|January 7, 2010
[Chemotherapy induced emesis: pathophysiology and prevention]A Mailliez, J Bonneterre
Gynecologie, Obstetrique & Fertilite|January 14, 2014
[What do clinicians do with the results of the systematic staging imaging at the time of the breast cancer diagnosis?]A Turpin, A Mailliez, P Vennin, et al.
British Journal of Cancer|August 26, 2010
Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patientsA Mailliez, C Baldini, J T Van, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 6, 2024
Breast Cancer Prognosis in Young BRCA1/BRCA2 Mutation Carriers: A Retrospective Hospital-based Cohort StudyF Hego, M Barthoulot, S Chretien, et al.
Journal of Neuro-Oncology|March 5, 2013
A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancerE Le Rhun, S Taillibert, F Zairi, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2018
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trialS A Hurvitz, R G W Quek, N C Turner, et al.
ESMO Open|May 4, 2024
Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohortN Epaillard, A Lusque, W Jacot, et al.
ESMO Open|July 25, 2021
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)D Dano, A Lardy-Cleaud, A Monneur, et al.
ESMO Open|September 18, 2025
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohortR Varnier, D Pérol, W Jacot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)H Bonnefoi, T Grellety, O Tredan, et al.
Pageof 2